| Authors: |
van Riet E; Tuberculosis Vaccine Initiative, Lelystad, Netherlands; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands. Electronic address: elly.vanriet@tbvi.eu., Corleis B; Institute of Immunology, Friedrich-Loeffler Institut, Insel Riems, Greifswald, Germany., Giersing BK; Department of Immunizations, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland., Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa., Burhan E; Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia-Persahabatan Hospital, Jakarta, Indonesia; Respiratory Programmatic Implementation and Research Institute, Jakarta, Indonesia., Jassat W; Tuberculosis Control and Management Cluster, National Department of Health, Pretoria, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., White RG; Tuberculosis Modelling Group, Tuberculosis Centre, Vaccine Centre, and Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK., Lewinsohn D; Department of Medicine, Oregon Health and Science University, Portland, OR, USA., Cobelens F; Department of Global Health and Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands. |
